Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/7697
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: The CF salt controversy: In vivo observations and therapeutic approaches
Author: Tarran, R.
Grubb, B.
Parsons, D.
Picher, M.
Hirsch, A.
Davis, C.
Boucher, R.
Citation: Molecular Cell, 2001; 8(1):149-158
Publisher: Cell Press
Issue Date: 2001
ISSN: 1097-2765
1097-4164
Abstract: There is controversy over whether abnormalities in the salt concentration or volume of airway surface liquid (ASL) initiate cystic fibrosis (CF) airway disease. In vivo studies of CF mouse nasal epithelia revealed an increase in goblet cell number that was associated with decreased ASL volume rather than abnormal [Cl−]. Aerosolization of osmolytes in vivo failed to raise ASL volume. In vitro studies revealed that osmolytes and pharmacological agents were effective in producing isotonic volume responses in human airway epithelia but were typically short acting and less effective in CF cultures with prolonged volume hyperabsorption and mucus accumulation. These data show that (1) therapies can be designed to normalize ASL volume, without producing deleterious compositional changes in ASL, and (2) therapeutic efficacy will likely depend on development of long-acting pharmacologic agents and/or an increased efficiency of osmolyte delivery.
Keywords: Goblet Cells
Nasal Mucosa
Respiratory Mucosa
Cells, Cultured
Mucus
Animals
Mice, Inbred C57BL
Humans
Mice
Cystic Fibrosis
Disease Models, Animal
Sodium Chloride
Amiloride
Raffinose
Uridine Triphosphate
Diuretics
Pulmonary Surfactants
Aerosols
Microscopy, Confocal
Microdialysis
Ion Transport
Osmolar Concentration
Rights: Copyright © 2001 Cell Press. All rights reserved.
DOI: 10.1016/S1097-2765(01)00286-6
Published version: http://dx.doi.org/10.1016/s1097-2765(01)00286-6
Appears in Collections:Aurora harvest
Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.